https://scholars.lib.ntu.edu.tw/handle/123456789/641634
標題: | Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol | 作者: | Schwartz, Gregory G Szarek, Michael Bittner, Vera A Diaz, Rafael Goodman, Shaun G Jukema, J Wouter Landmesser, Ulf López-Jaramillo, Patricio Manvelian, Garen Pordy, Robert Scemama, Michel Sinnaeve, Peter R White, Harvey D Gabriel Steg, Ph JUEY-JEN HWANG |
關鍵字: | PCSK9 inhibitor; acute coronary syndrome; lipoprotein(a); low-density lipoprotein cholesterol | 公開日期: | 3-八月-2021 | 卷: | 78 | 期: | 5 | 起(迄)頁: | 421 | 來源出版物: | Journal of the American College of Cardiology | 摘要: | Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients with LDL-C near 70 mg/dL. Lipoprotein(a) levels may influence residual risk. |
URI: | https://www.scopus.com/record/display.uri?eid=2-s2.0-85110291084&doi=10.1016%2fj.jacc.2021.04.102&origin=inward&txGid=fa0a0f1033879bc6a1a9f1dcd4e0c6a8 https://scholars.lib.ntu.edu.tw/handle/123456789/641634 |
ISSN: | 07351097 | DOI: | 10.1016/j.jacc.2021.04.102 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。